RNA — Avidity Biosciences Share Price
0.000.00%
Last trade - 00:00- $3.71bn
- $2.21bn
- $10.90m
- 49
- 11
- 39
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.6 | ||
| Price to Tang. Book | 2.6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 340.22 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -25.85% | ||
| Return on Equity | -33.47% | ||
| Operating Margin | -3477.43% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.79 | 9.33 | 9.22 | 9.56 | 10.9 | 6.36 | 14.96 | 36.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
Directors
- Troy Wilson CHM (52)
- Sarah Boyce PRE (49)
- Michael Maclean CFO (55)
- W. Michael Flanagan CTO (59)
- Arthur Levin CSO (67)
- Carsten Boess IND (54)
- Noreen Henig IND (56)
- Edward Kaye IND (72)
- Jean Kim IND (47)
- Eric Mosbrooker IND (53)
- Tamar Thompson IND (47)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 13th, 2012
- Public Since
- June 12th, 2020
- No. of Shareholders
- 19
- No. of Employees
- 391
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 120,212,301
- Address
- 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO, 92121
- Web
- https://www.aviditybiosciences.com/
- Phone
- +1 8584017900
- Contact
- Geoffrey Grande
- Auditors
- BDO USA, LLP
Upcoming Events for RNA
Avidity Biosciences Inc Annual Shareholders Meeting
Q2 2025 Avidity Biosciences Inc Earnings Release
Similar to RNA
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Avidity Biosciences share price?
As of Today at 19:27 UTC, shares in Avidity Biosciences are trading at $30.84. This share price information is delayed by 15 minutes.
How has the Avidity Biosciences share price performed this year?
Shares in Avidity Biosciences last closed at $30.84 and the price had moved by +29.42% over the past 365 days. In terms of relative price strength the Avidity Biosciences share price has outperformed the S&P500 Index by +19.46% over the past year.
What are the analyst and broker recommendations for Avidity Biosciences?
The overall consensus recommendation for Avidity Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Avidity Biosciences dividend yield?
Avidity Biosciences does not currently pay a dividend.
Does Avidity Biosciences pay a dividend?
Avidity Biosciences does not currently pay a dividend.
When does Avidity Biosciences next pay dividends?
Avidity Biosciences does not currently pay a dividend.
How do I buy Avidity Biosciences shares?
To buy shares in Avidity Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Avidity Biosciences?
As of the previous close price of $30.84, shares in Avidity Biosciences had a market capitalisation of $3.71bn.
Where are Avidity Biosciences shares listed?
Here are the trading details for Avidity Biosciences:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: RNA
What kind of share is Avidity Biosciences?
Based on an overall assessment of its quality, value and momentum Avidity Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Avidity Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Avidity Biosciences is $66.85. That is 116.76% above the last closing price of $30.84.
Analysts covering Avidity Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$3.90 for the next financial year.
Find out moreWhat is the trend in the Avidity Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avidity Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -27.94%.
As of the last closing price of $30.84, shares in Avidity Biosciences were trading -18.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Avidity Biosciences PE Ratio?
The Avidity Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $30.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Avidity Biosciences?
Avidity Biosciences' management team is headed by:
- Troy Wilson - CHM
- Sarah Boyce - PRE
- Michael Maclean - CFO
- W. Michael Flanagan - CTO
- Arthur Levin - CSO
- Carsten Boess - IND
- Noreen Henig - IND
- Edward Kaye - IND
- Jean Kim - IND
- Eric Mosbrooker - IND
- Tamar Thompson - IND